My ePortfolio Register   

ESTRO 2010 /
PARP inhibitors

12th - 16th Sep 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.10
Views: 5847
Rating:

Professor Thomas Helleday, Oxford University, UK and Prof Anthony Chalmers, University of Glasgow, UK.

Prof Helleday and Prof Chalmers speak to ecancer.tv about PARP inhibitors, their significance to cancer treatment and their potential for use in combination with radiotherapy. PARP inhibitors allow clinicians to target treatment specifically at the cancer cells which dramatically reduces side effects. Prof Helladay speaks about the progress that has been made bringing this technology into clinical trials and Prof Chalmers discusses the way that PARP inhibitors increase the radio-sensitivity of tumours without increasing the sensitivity of surrounding healthy tissue. Among the challenges now faced is the development of a simple and fast test to detect which cells are particularly susceptible to the PARP radiotherapy combination. Prof Chalmers and Prof Helleday speak about their hopes for developments in imaging technology, the possibility of combining PARP and radiotherapy with further radio-sensitisers and the development of recombination inhibitors.

Categories:

Imaging · Radiotherapy · ESTRO 2010

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence